Abiopharma

🔍 Torley Helen (Executive)

Company: HALOZYME THERAPEUTICS, INC. (HALO)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Common Stock at $8.11 per share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 753,719.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 300 shares of Common Stock at $72.485 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 753,419.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 16,288 shares of Common Stock at $73.698 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 737,131.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 3,412 shares of Common Stock at $74.147 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 733,719.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Acquired 20,000 shares of Common Stock at $8.11 per share (Direct)
  Date: 2025-09-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 753,719.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 9,500 shares of Common Stock at $74.22 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 744,219.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 10,500 shares of Common Stock at $74.632 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 733,719.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Acquired 20,000 shares of Common Stock at $8.11 per share (Direct)
  Date: 2025-09-04 | Code: M | equity_swap_involved: 0 | shares_owned_after: 753,719.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 9,900 shares of Common Stock at $73.536 per share (Direct)
  Date: 2025-09-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 743,819.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 7,800 shares of Common Stock at $74.327 per share (Direct)
  Date: 2025-09-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 736,019.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 2,300 shares of Common Stock at $75.224 per share (Direct)
  Date: 2025-09-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 733,719.00 | transaction_form_type: 4 | Footnotes: F1, F9
• Sold 20,000 shares of Option to Purchase Common Stock at $8.11 per share (Derivative)
  Date: 2025-09-02 | Code: M | Expires: 2026-02-03 | equity_swap_involved: 0 | shares_owned_after: 176,569.00 | transaction_form_type: 4 | Footnotes: F1, F10
• Sold 20,000 shares of Option to Purchase Common Stock at $8.11 per share (Derivative)
  Date: 2025-09-03 | Code: M | Expires: 2026-02-03 | equity_swap_involved: 0 | shares_owned_after: 156,569.00 | transaction_form_type: 4 | Footnotes: F1, F10
• Sold 20,000 shares of Option to Purchase Common Stock at $8.11 per share (Derivative)
  Date: 2025-09-04 | Code: M | Expires: 2026-02-03 | equity_swap_involved: 0 | shares_owned_after: 136,569.00 | transaction_form_type: 4 | Footnotes: F1, F10

Footnotes:

• F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.
• F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.99 to $72.81. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.03 to $74.02. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.03 to $74.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.48 to $74.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.48 to $74.93. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.06 to $74.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.06 to $74.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.11 to $75.44. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F10: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.